Rice Hall James & Associates LLC Sells 66,962 Shares of ADMA Biologics Inc $ADMA

Rice Hall James & Associates LLC reduced its stake in ADMA Biologics Inc (NASDAQ:ADMA) by 17.1% in the 3rd quarter, HoldingsChannel reports. The firm owned 323,653 shares of the biotechnology company’s stock after selling 66,962 shares during the quarter. Rice Hall James & Associates LLC’s holdings in ADMA Biologics were worth $4,745,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in ADMA. Smartleaf Asset Management LLC grew its stake in shares of ADMA Biologics by 161.4% in the 1st quarter. Smartleaf Asset Management LLC now owns 2,418 shares of the biotechnology company’s stock valued at $49,000 after buying an additional 1,493 shares during the period. FORA Capital LLC acquired a new stake in ADMA Biologics in the first quarter valued at approximately $541,000. Ieq Capital LLC increased its holdings in shares of ADMA Biologics by 8.2% during the first quarter. Ieq Capital LLC now owns 22,174 shares of the biotechnology company’s stock valued at $440,000 after acquiring an additional 1,672 shares in the last quarter. State of Wyoming bought a new stake in shares of ADMA Biologics during the first quarter valued at approximately $189,000. Finally, Driehaus Capital Management LLC raised its position in shares of ADMA Biologics by 114.9% during the first quarter. Driehaus Capital Management LLC now owns 2,946,570 shares of the biotechnology company’s stock worth $58,460,000 after purchasing an additional 1,575,363 shares during the period. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Stock Down 1.3%

Shares of NASDAQ:ADMA opened at $19.28 on Friday. The business’s 50 day moving average is $17.43 and its 200 day moving average is $17.23. ADMA Biologics Inc has a 12-month low of $13.50 and a 12-month high of $25.67. The stock has a market cap of $4.59 billion, a price-to-earnings ratio of 22.42 and a beta of 0.43. The company has a quick ratio of 3.65, a current ratio of 7.13 and a debt-to-equity ratio of 0.18.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Wednesday, November 5th. The biotechnology company reported $0.16 earnings per share for the quarter, meeting the consensus estimate of $0.16. The business had revenue of $134.22 million for the quarter, compared to analysts’ expectations of $131.20 million. ADMA Biologics had a return on equity of 36.52% and a net margin of 42.87%.The business’s revenue was up 12.0% on a year-over-year basis. During the same period last year, the business earned $0.15 EPS. On average, sell-side analysts forecast that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “hold (c)” rating on shares of ADMA Biologics in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $28.50.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.